BIOMAT Database Logo BIOMAT Database Logo

Interstitial pneumonitis after infliximab therapy for Crohn's disease. 2006

Mark Weatherhead, and Steven Masson, and Stephen J Bourke, and Melanie C Gunn, and Graham P Burns

UI MeSH Term Description Entries
D003424 Crohn Disease A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients. Colitis, Granulomatous,Enteritis, Granulomatous,Enteritis, Regional,Ileitis, Regional,Ileitis, Terminal,Ileocolitis,Crohn's Disease,Crohn's Enteritis,Inflammatory Bowel Disease 1,Regional Enteritis,Crohns Disease,Granulomatous Colitis,Granulomatous Enteritis,Regional Ileitides,Regional Ileitis,Terminal Ileitis
D005765 Gastrointestinal Agents Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. Digestants,Gastric Agents,Gastric Drugs,Gastrointestinal Drugs,Agents, Gastric,Agents, Gastrointestinal,Drugs, Gastric,Drugs, Gastrointestinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069285 Infliximab A chimeric monoclonal antibody to TNF-ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE. Inflectra,Infliximab-abda,Infliximab-dyyb,MAb cA2,Monoclonal Antibody cA2,Remicade,Renflexis,Antibody cA2, Monoclonal,Infliximab abda,Infliximab dyyb,cA2, Monoclonal Antibody
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D017563 Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features. Diffuse Parenchymal Lung Disease,Diffuse Parenchymal Lung Diseases,Interstitial Lung Disease,Interstitial Lung Diseases,Pneumonia, Interstitial,Pneumonitis, Interstitial,Interstitial Pneumonia,Interstitial Pneumonias,Interstitial Pneumonitides,Interstitial Pneumonitis,Lung Disease, Interstitial,Pneumonias, Interstitial,Pneumonitides, Interstitial

Related Publications

Mark Weatherhead, and Steven Masson, and Stephen J Bourke, and Melanie C Gunn, and Graham P Burns
Interstitial pneumonitis associated with infliximab therapy.
June 2006, The Journal of rheumatology,
Mark Weatherhead, and Steven Masson, and Stephen J Bourke, and Melanie C Gunn, and Graham P Burns
Severe interstitial pneumonitis associated with infliximab therapy.
January 2004, Scandinavian journal of rheumatology,
Mark Weatherhead, and Steven Masson, and Stephen J Bourke, and Melanie C Gunn, and Graham P Burns
Colon cancer after infliximab therapy for Crohn's disease.
December 2010, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Mark Weatherhead, and Steven Masson, and Stephen J Bourke, and Melanie C Gunn, and Graham P Burns
Infliximab therapy for pediatric Crohn's disease.
December 2007, Expert opinion on biological therapy,
Mark Weatherhead, and Steven Masson, and Stephen J Bourke, and Melanie C Gunn, and Graham P Burns
Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment.
December 2009, Rheumatology international,
Mark Weatherhead, and Steven Masson, and Stephen J Bourke, and Melanie C Gunn, and Graham P Burns
Large Bowel Progressive Stricture after Infliximab Therapy for Crohn's Disease.
August 2018, Internal medicine (Tokyo, Japan),
Mark Weatherhead, and Steven Masson, and Stephen J Bourke, and Melanie C Gunn, and Graham P Burns
Successful infliximab therapy for oral Crohn's disease.
April 2006, Inflammatory bowel diseases,
Mark Weatherhead, and Steven Masson, and Stephen J Bourke, and Melanie C Gunn, and Graham P Burns
Infliximab maintenance therapy for fistulizing Crohn's disease.
February 2004, The New England journal of medicine,
Mark Weatherhead, and Steven Masson, and Stephen J Bourke, and Melanie C Gunn, and Graham P Burns
[Infliximab therapy for Crohn's disease anoperineal lesions].
November 2001, Gastroenterologie clinique et biologique,
Mark Weatherhead, and Steven Masson, and Stephen J Bourke, and Melanie C Gunn, and Graham P Burns
Sarcoidosis during infliximab therapy for Crohn's disease.
May 2010, The Journal of dermatology,
Copied contents to your clipboard!